Navigation Links
Researchers at Axial Biotech Develop a DNA Test for Scoliosis
Date:9/11/2008

Study results presented at the Scoliosis Research Society Meeting in Salt

Lake City

SALT LAKE CITY, Sept. 11 /PRNewswire/ -- Researchers at Axial Biotech, Inc., announced today that they have identified specific genetic markers for scoliosis. The data from this research made it possible for the development of a DNA-based prognostic test for spinal curve progression in patients with Adolescent Idiopathic Scoliosis.

This groundbreaking research was presented to members of the Scoliosis Research Society (SRS) on Thursday, September 11, 2008 at the 43rd Annual SRS Meeting held in Salt Lake City.

Scoliosis is an inherited disease that occurs when the spine twists and develops a sideways curve. When the cause of scoliosis is unknown, for patients between the age of 9 and 13, it is called Adolescent Idiopathic Scoliosis (AIS). If an AIS curve progresses, the most widely accepted treatments are serial spinal bracing or spinal fusion surgery.

The scoliosis research, which began in 2003 and ended last month, involved collecting DNA samples from over 9,000 patients from 85 clinical sites throughout the world. All patient samples were analyzed on several technology platforms and specific disease classifications were evaluated by the review of x-rays and medical records provided from physicians who were treating patients enrolled in this study.

"These landmark studies have provided researchers with greater insights into the genetic markers associated with spinal curve progression," stated Ken Ward, M.D., Chief Scientific Officer for Axial Biotech. "The AIS Prognostic Test, which can determine whether a child has a mild or more severe likelihood of curve progression, at the very first presentation of symptoms, may provide comfort to thousands of children and their families every year. This study reinforces the importance of research that may lead to new treatment options for scoliosis patients."

"We believe that the use of DNA-based testing to determine the likelihood of disease progression will initiate a new era of improvements in spine health," says Jim Ogilvie, M.D, Chief Medical Consultant. "From a clinical standpoint, this test delivers the promise of personalized medicine to spine surgeons who will now have the opportunity to determine the likely disease progression for an individual AIS patient, and can make evidence-based recommendations for patient-specific treatment options."

Geneticists at Axial Biotech are currently analyzing the data from the 9,000 patients studied, to identify genetic factors that initially cause this disease, and the company anticipates that soon it may largely understand the specific biology for this aggressive and crippling disease, and hopes to develop molecular treatments for scoliosis patients.

The AIS prognostic test will be marketed under the trade name of ScoliScore(TM) and will be marketed and distributed by DePuy Spine, a Johnson & Johnson company.

About Axial Biotech

Axial Biotech, Inc. develops molecular diagnostic assays and motion preservation technologies for common spinal diseases and disorders. Axial has developed the first DNA-based prognostic test for Adolescent Idiopathic Scoliosis. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains
2. Rapid Test for Pathogens Developed By K-State Researchers Could Be Used to Detect Diseases Used By Bioterrorists
3. Dallas Researchers Find Compression Stockings Improperly Used
4. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
5. Pediatric Researchers Find Possible Master Switch Gene in Juvenile Arthritis
6. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
7. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
8. NARSAD Researchers Identify Specific Genes and Family Traits Linked to Schizophrenia, Bipolar Disorder and Depression
9. Cardiovascular Researchers Use MEDIHONEY(TM) on Sternal Infections Following Open-Heart Procedures
10. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
11. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):